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Abstract
Heparin is an anticoagulant medicinally used to inhibit blood clotting. It is commonly
administered to patients requiring surgery or kidney dialysis. Presently, it is produced
from animal tissues, but a recent contamination crisis pointed to the need for a safer
source of the drug. Our project seeks to develop a rapid, inexpensive, high-throughput
assay to quantitate the production of heparin and other glycosaminoglycans (GAGs) from
cultured mammalian cells. In order to quantitate heparin from cell culture media, a
purification method is needed to separate GAGs from interfering constituents in the
media. We developed a purification protocol that absorbs Pluronic and most proteins to
Sep-Pak C-18 cartridges, followed by ultrafiltration through 5 kDa cutoff Vivaspin
centrifugal concentrators. The purified GAGs are then quantitated by a microcarbazole
assay.
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Introduction
Heparin is a highly sulfated glycosaminoglycan (GAG) composed of repeating
disaccharides of L-iduronic acid or D-glucuronic acid and N-acetyl-D-glucosamine¹. It is
a hydrophilic molecule with the highest negative charge density among all known
biological molecules² and contains chains with molecular weights ranging from 6,000 to
30,000 Daltons³.
Heparin is one of the most widely used anticoagulants in the pharmaceutical
industry¹. Currently, it is extracted from animal tissues, including porcine intestines and
bovine lungs⁴. A health crisis in 2008 from contamination caused by an oversulfated
chondroitin sulfate⁵ led to approximately 100 deaths in the United States², pointing to
the need for a safer source of heparin.
One goal of the Sharfstein lab is to metabolically engineer Chinese hamster ovary
(CHO) cells to produce heparin⁴. CHO cells are capable of producing heparan sulfate
(HS), a less sulfated form of heparin, naturally⁴. Since heparin and HS form afamily of
GAGs that share the same biosynthetic pathway⁶ , CHO cells present a possible new
source of heparin. As part of this endeavor, a GAG purification method was previously
established to isolate and concentrate GAGs⁴, as well as prevent interferencefrom other
components of culture media during the subsequent quantitation step using the
microcarbazole assay, which detects the concentration of the purified GAGs⁷ .
Carbazole-based quantification utilizes sodium tetraborate in sulfuric acid to hydrolyze
the GAGs into uronic acid and glycosamine⁷. Carbazole subsequently reacts with the
uronic acid, yielding a colored product that can be quantitated spectrophotometrically⁷.
The current purification protocol is costly both in time and materials⁴. Thus, our project
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seeks to develop a rapid, inexpensive, high-throughput assay to purify and quantitate the
production of heparin and other glycosaminoglycans (GAGs) from cultured mammalian
cells.
There are two key components of cell culture media that interfere with the
microcarbazole assay whose characteristics we focus on to build our new protocol,
Pluronic and glucose.
First, Pluronic F68 is used in cell culture as an anti-foaming agent and to protect
cell membranes from shearing⁸. Pluronic F68 is a poloxam er and contains a hydrophilic
poly(ethylene oxide) and hydrophobic poly(propylene oxide)⁹.

T hus, to rem ove

Pluronic and other hydrophobic contaminants, we employ liquid chromatography using
Waters Sep-Pak C-18 classic cartridges, which utilize a strongly hydrophobic silica-based
bonded phase¹⁰.
Second, glucose is added to cell culture systems to act as a primary source of fuel
for animal cells, which are heterotrophs who obtain energy from coupled oxidationreduction reactions¹¹. Glucose is a strongly hydrophilic hexose sugar¹² with a molecular
weight of 180 Da. Thus, to remove glucose and other small interfering molecules, we
employ ultrafiltration using Sartorius Vivaspin centrifugal concentrators, which utilize a
semi-permeable membrane to separate solutions based on size¹³.
Our hypothesis is that the new GAG purification protocol utilizing liquid
chromatography and ultrafiltration can achieve its purpose of heparin and GAG isolation
while greatly reducing the time and cost required to run the experiments.
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Materials & Methods
Sodium heparin (lot #SLBL6351V) was from Sigma-Aldrich. Sep-Pak C-18 classic
cartridges (WAT051910) were from Waters.

Vivaspin 6 (3 kDa cutoff) (lot

#1703005VS) and Vivaspin 15R (5 kDa cutoff) (lot #1701014VS) centrifugal
concentrators were from Sartorius. A Thermo Scientific 8 x 50 mL fixed angle rotor was
used for all centrifugations.

A. Microcarbazole Assay¹⁴
To quantitate the concentration of heparin, the colorimetric microcarbazole assay was
employed. Two separate revisions of the microcarbazole assay were used.

Revised Microcarbazole Assay #1
A revised assay was developed to reduce the time required by combining the two heating
steps and separate addition of reagents into one. Additionally, sulfamide was used to
react with some of the byproducts that give false color. Twenty five-µL samples were
added to a Thermo Scientific PCR plate. 2.5-µL of 4M sulfamide was added, as well as
175 µL of reagent A (2-mL of 1.25 M sodium tetraborate decahydrate in hot water and
98-mL of 99% sulfuric acid) to hydrolyze and dehydrate the uronic acid of heparin into
furans, and 5 µL of reagent B (1.25 g/L carbazole in absolute ethanol) to react the furans
with carbazole to form a colored compound. The plate was covered with a plastic film
and heated in the thermal cycler at 100ºC for 15 minutes to enable the hydrolysis and
carbazole reactions, followed by chilling to 4°C. 150 µL of each sample was transferred
to a Costar 96-well plate and the absorbance was measured at 525 nm using a Fisher
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Scientific microplate reader (instrument: Infinite 200, equipment number: 10294608) and
Tecan i-control application.

Heparin Standard Curve Using Revised Microcarbazole Assay #1
To test the effectiveness of the revised microcarbazole assay #1, a 1 mg/mL heparin
solution was used to create a standard curve. The sample concentrations used were 0,
0.5, 5, 10, and 20 µg/25 µL sample.

Revised Microcarbazole Assay #2
A second revised assay using a lower reaction temperature was developed to reduce the
effects of a high temperature, such as charring that produces false color. Additionally, to
reduce the propagation of pipetting errors, an Eppendorf Repeater M4 Manual Handheld
Pipette Dispenser was used to add all reagents (using 0.1 mL pipette tips for sulfamide
and reagent B and 5 mL tips for reagent A), and the 25-µL samples were added directly
to the 96-well plate. The repeater pipette was used to add 2-µL of 4M sulfamic acid, 5
µL of reagent B, and 150 µL of reagent A. The plate was then incubated on a hot plate at
60°C for 1 hour (a study of different heating times was conducted and 1 hour was chosen
as optimal).

The absorbance was measured at 525 nm using a Fisher Scientific

microplate reader and Tecan i-control application.
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Heparin Standard Curve Using Revised Microcarbazole Assay #2
To test the effectiveness of revised microcarbazole assay #2, a 1 mg/mL heparin solution
was used to create a standard curve. The sample concentrations used were 0, 2, 2.5, 5,
10, 15, 20, and 25 µg/25 µL sample.

Heparin Standard Curve with Repeater Pipette Using Revised Microcarbazole Assay #2
To increase the accuracy of the standard curve, a repeater pipette was used to create the
standard curve using a 1 mg/mL heparin solution. The sample concentrations used were
0, 5, 10, 15, 20, 22, and 24 µg/25 µL sample.

B. Liquid Chromatography Using Waters Sep-Pak C-18 Classic Cartridges
To remove Pluronic F68 in solution, liquid chromatography experiments were performed
using Waters Sep-Pak C-18 classic cartridges.

Using Sep-Pak C-18 Classic Cartridges
The Sep-Pak C-18 cartridge was washed using a syringe with 5 mL of ethanol and 2 x 5
mL of water. The sample was then passed through the cartridge, followed by one 1-mL
water wash.

Removing Pluronic in Solution
Two-mL of a 10 mg/mL solution of Sigma-Aldrich Pluronic F68 was passed through one
Sep-Pak C-18 cartridge prepared as described above (but followed by two water washes
to maximize recovery) with the objective of retaining the Pluronic in the column. The
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flow-through and washes were placed in a pre-weighed 15 mL conical centrifuge tube,
frozen, lyophilized, and reweighed to determine how much Pluronic did not adsorb to the
C-18 resin.

C. Ultrafiltration Using Sartorius Vivaspin 6 Centrifugal Concentrators
To test the ability of the Vivaspin centrifugal concentrators to retain heparin and remove
glucose from the solution, ultrafiltration experiments were conducted using Sartorius
Vivaspin 6 centrifugal concentrators.

Retaining Heparin in Solution
Six-mL of a 2 mg/mL heparin solution was added to a Vivaspin 6 centrifugal
concentrator and two 25-µL samples were reserved. The filter was centrifuged at 10,000
x g at 18ºC for 45 minutes and two 25-µL samples of the permeate were reserved. Six
mL of water was added to the retentate and two 25-µL samples were reserved. The
centrifugal concentrator was then centrifuged once more and the samples reserved as
before. All samples were transferred into a PCR plate and analyzed by the revised
microcarbazole assay #1.

Removing Glucose in Solution
Six-mL of a 0.1% glucose solution was added to a Vivaspin 6 centrifugal concentrator
and two 25-µL samples were reserved. The filter was centrifuged at 10,000 x g at 18ºC
for 45 minutes and two 25-µL samples of the permeate were reserved. Six mL of water
was added to the retentate before two 25-µL samples were reserved. The centrifugal
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concentrator was then centrifuged once more and the samples reserved as before. All
samples were transferred into a PCR plate and analyzed by the revised microcarbazole
assay #1.

D. GAG Purification Experiments Using Ultrafiltration with Sartorius Vivaspin 15R
Centrifugal Concentrators & Liquid Chromatography with Waters Sep-Pak C-18
Classic Cartridges
To determine if heparin could be isolated in various larger solutions, GAG purification
experiments were performed using liquid chromatography with Waters Sep-Pak C-18
classic cartridges and ultrafiltration with Sartorius Vivaspin 15R centrifugal
concentrators.

Isolating Heparin from Pluronic and Glucose in Solution
In one conical tube, 4 mL of nanopure water was added to 1-mL of a 2 mg/mL heparin
solution. 100 mg of glucose (a higher concentration was used to better see any residual
glucose after spins) and 100 mg of Pluronic F68 was added to 10 mL of water, and 4-mL
of the Pluronic-glucose solution was added to a second conical tube containing 1-mL of a
2 mg/mL heparin solution. Three 25-µL samples were reserved from both conical tubes.
Both solutions were passed through three Sep-Pak C-18 cartridges prepared as described
above, and three 25-µL samples were reserved from the total eluent. The solutions were
then each placed in a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g
at 18ºC for 45 minutes, and three 25-µL samples were reserved from the permeate. Ten
mL of water was added to the retentate before three 25-µL samples were taken. The
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centrifugal concentrator was then centrifuged twice more and the samples reserved as
before. All samples were transferred into a 96-well plate and analyzed by the revised
microcarbazole assay #2.

Isolating Heparin from Interfering Components in Fresh Medium
In one conical tube, 4 mL of nanopure water was added to 1-mL of a 2 mg/mL heparin
solution. In a second conical tube, 4 mL of medium was added to 1-mL of a 2 mg/mL
heparin solution. In a third conical tube, 4 mL of medium was added to 1 mL of
nanopure water. Three 25-µL samples were reserved from each tube. All three solutions
were passed through three Sep-Pak C-18 cartridges prepared as described above, and
three 25-µL samples were reserved from the total eluent. The solutions were then each
placed in a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g at 18ºC
for 45 minutes, and three 25-µL samples were reserved from the permeate. Ten mL of
water was added to the retentate before three 25-µL samples were taken. The centrifugal
concentrator was then centrifuged twice more and the samples reserved as before. All
samples were transferred into a 96-well plate and analyzed by the revised microcarbazole
assay #2.

Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Samples
Eight mL of conditioned medium sample (names are specified in Table 1) was added to a
conical tube and three 25-µL samples were reserved. The samples were purified using a
Sep-Pak C-18 cartridge, and three 25-µL samples were reserved. This larger-volume
sample was added to a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x
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g at 18ºC (centrifugation times specified in Table 1). The centrifugations were repeated
twice more. After each centrifugation, three 25-µL samples were reserved from the
permeate and 10 mL of water added to the retentate (except for the final retentate, which
was filled to the volume indicated in Table 1) before three 25-µL samples were reserved.
Upon exploring various centrifugation times, 45 minutes was determined to be optimal
when the tip of the membrane was properly oriented towards the center of the centrifuge.
All samples were transferred into a 96-well plate and analyzed by the revised
microcarbazole assay #2.

Table 1: Specifications of the medium sample name, time for each centrifugation, and
amount of water added to the final retentate before samples were taken from experiment
of the recovery of heparin-like glycosaminoglycans from conditioned medium samples.
Name of Medium Sample Used
C5 Epi 11/2/17 3rd fed Batch = 50 mL
C5 Epi 2 mM B 7/13/17
C5 Epi 4 mM C 7/18/17

Centrifugation Time
(Minutes)
75
45
110

Water Added to
Final Retentate (mL)
0.5
10
10

E. Comparing Old GAG Purification Method & New GAG Purification Method
To compare the recovery of heparin-like glycosaminoglycans from conditioned media
samples, the old GAG purification method⁴ and new GAG purification method (liquid
chromatography using Sep-Pak C-18 classic cartridges and ultrafiltration using Vivaspin
15R centrifugal concentrators) were performed three times each using the same
conditioned media sample (combined ChS Excell A 8/20/17 and ChS Hycell B 8/19).
Six 8-mL samples of conditioned media were added to separate conical tubes. GAGs
from three of the samples were purified using the original GAG purification method⁴,
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and the resulting purified GAGs were reserved in separate Eppendorf tubes. The other
three samples were purified using the new GAG purification method: solutions were
passed through three Sep-Pak C-18 cartridges prepared as described above, and three 25µL samples were reserved from the total eluent. The solutions were then each placed in a
Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g at 18ºC for 45
minutes, and three 25-µL samples were reserved from the permeate. Ten mL of water
was added to the retentate before three 25-µL samples were taken. The centrifugal
concentrator was then centrifuged twice more and the samples reserved as before with
one exception: the final retentate alone was transferred to an Eppendorf tube, and 100 µL
of water was added to the centrifugal concentrator to recover all product, which was also
transferred to the Eppendorf tube. Two 25-uL samples of all six experiments were
transferred into a 96-well plate and analyzed by the revised microcarbazole assay #2.
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Results
A. Microcarbazole Assay

Heparin Standard Curve Using Revised Microcarbazole Assay #1
To reduce the amount of time required for the microcarbazole assay and the production of
false color, the two heating steps were combined into one and sulfamide was added to
prevent false color. The revised microcarbazole assay #1 was performed to detect the
concentration of heparin by measuring the absorbance at 525 nm. In Figure 1, the
absorbance values of a standard curve that utilizes the revised microcarbazole assay #1
are reported. The revised microcarbazole assay #1 was able to accurately quantitate
heparin in solution.

Absorbance (at 525 nm)

0.7
0.6

y = 0.011x + 0.3497

0.5

R2 = 0.9929

0.4
0.3
0.2
0.1
0
0

5

10
15
Concentration (μg/μL)

20

25

Figure 1: Heparin standard curve using the revised microcarbazole assay #1.

Heparin Standard Curve Using Revised Microcarbazole Assay #2
To reduce the propagation of pipetting errors and the effects of a high temperature, the
revised microcarbazole assay #1 was further revised to utilize a repeater pipette to add the
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reagents, add the samples directly to a 96-well plate, and perform the assay at a lower
temperature (60°) by using a hot plate instead of a thermal cycler to heat the samples.
The revised microcarbazole assay #2 was performed in triplicate to detect the
concentration of heparin by measuring the absorbance at 525 nm. In Figure 2, the
absorbance values of a standard curve that utilizes the revised microcarbazole assay #2
are reported. The revised microcarbazole assay #2 was able to accurately quantitate
heparin in solution.
0.9

y = 0.0193x + 0.3243
R2 = 0.9353

Absorbance (at 525 nm)

0.8

y = 0.0193x + 0.2627

0.7

R2 = 0.9707

0.6

y = 0.015x + 0.256

15 Mi ns

R2 = 0.9541

0.5

30 Mi ns

y = 0.0068x + 0.245

0.4

45 Mi ns

R2 = 0.8375

60 Mi ns

0.3

y = 0.0016x + 0.2453
R² = 0.4694

0.2

90 Mi ns

0.1
0
0

5

10

15
Concentration (μg/μL)

20

25

30

Figure 2: Heparin standard curve using a revised microcarbazole assay #2 at various
heating times. The revised microcarbazole assay #2 was performed in triplicate. Error
bars represent the standard deviation of triplicate measurements of revised
microcarbazole assay #2.

Heparin Standard Curve with Repeater Pipette Using Revised Microcarbazole Assay #2
To increase the accuracy of the standard curve using the revised microcarbazole assay #2,
a repeater pipette was used to add the heparin samples. The revised microcarbazole assay
#2 was performed in triplicate to detect the concentration of heparin by measuring the
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absorbance at 525 nm. In Figure 3, the absorbance values of the standard curve that
utilizes a repeater pipette and the revised microcarbazole assay #2 are reported. The
repeater pipette was able to improve the quantitation of heparin using the revised
microcarbazole assay #2.

Absorbance (at 525 nm)

1.6
1.4

y = 0.0419x + 0.294

1.2

R2 = 0.998

1
0.8
0.6
0.4
0.2
0
0

5

10
15
Concentration (μg/μL)

20

25

Figure 3: Heparin standard curve with a repeater pipette using the revised
microcarbazole assay #2 for 1 hour. The revised microcarbazole assay #2 was performed
in triplicate. Error bars represent the standard deviation of triplicate measurements of the
revised microcarbazole assay #2.

B. Liquid Chromatography Using Waters Sep-Pak C-18 Classic Cartridges

Removing Pluronic in Solution
To remove Pluronic from water, a liquid chromatography experiment using Sep-Pak C-18
classic cartridges, followed by a lyophilization experiment, were conducted. In Table 2,
the mass of the conical tube is reported both before (prior to the addition of Pluronic) and
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after the experiment, as well as the mass of Pluronic added to the conical tube. The
cartridges removed all of the starting 2-mL of 10 mg/mL Pluronic.

Table 2: Removal of Pluronic in solution during a liquid chromatography experiment
using Sep-Pak C-18 classic cartridges and a lyophilization experiment.
Mass Before Liquid
Chromatography &
Lyophilization (g)

Mass of Pluronic in
2 mL water (mg)

Mass After Liquid
Chromatography &
Lyophilization (g)

Difference
(mg)

6.8653

20

6.8653

0

C. Ultrafiltration Using Sartorius Vivaspin 6 Centrifugal Concentrators

Retaining Heparin in Solution
To determine if heparin could be retained using centrifugal concentrators, heparin in
solution was ultrafiltered using Vivaspin 6 centrifugal concentrators.

The revised

microcarbazole assay #1 was performed in duplicate to detect the concentration of
heparin by measuring the absorbance at 525 nm. In Figure 4, concentrations are reported
as a percentage of the starting absorbance value of heparin.
approximately all of the starting 6-mL of 2 mg/mL heparin.
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The filters retained

Percentage of Initial Heparin Absorption
(%)

Retention of Heparin with Ultrafiltration

160
140
120
100
80
60
40
20
0
Retentate #2

Retentate #1

Figure 4: Recovery of heparin from water during each stage of an ultrafiltration
experiment using Vivaspin 6 centrifugal concentrators.

The revised microcarbazole

assay #1 was performed in duplicate.

Removing Glucose in Solution
To determine if glucose could be removed using centrifugal concentrators, glucose in
solution was ultrafiltered using Vivaspin 6 centrifugal concentrators.

The revised

microcarbazole assay #1 was performed in duplicate to detect the concentration of
glucose by measuring the absorbance at 525 nm. In Figure 5, concentrations are reported
as a percentage of the starting absorbance value of glucose. Although the microcarbazole
assay is not quantitative for glucose, the filters appeared to remove approximately 96% of
the starting 6-mL of 0.1% glucose.
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Removal of Gluose with Ultrafiltration

Percentage of Initial Glucose
Interference Absorption (%)

30
25
20
15
10
5
0

Retentate #2

Retentate #1

Figure 5: Removal of glucose from water during each stage of an ultrafiltration
experiment using Vivaspin 6 centrifugal concentrators.

The revised microcarbazole

assay #1 was performed in duplicate.

D. GAG Purification Experiments Using Ultrafiltration with Sartorius Vivaspin 15R
Centrifugal Concentrators & Liquid Chromatography with Waters Sep-Pak C-18
Classic Cartridges

Isolating Heparin from Pluronic and Glucose in Solution
To isolate heparin from Pluronic and glucose in solution, a GAG purification experiment
utilizing liquid chromatography and ultrafiltration was conducted. Two samples (a 5-mL
solution of 2 mg/mL of heparin in water and a 5-mL solution of 2 mg/mL of heparin, 10
mg/mL of glucose, and 10 mg/mL of Pluronic) were purified by liquid chromatography
using Sep-Pak C-18 cartridges and ultrafiltration using Vivaspin 15R centrifugal
concentrators.

The revised microcarbazole assay #2 was performed to detect the
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concentration of heparin by measuring the absorbance at 525 nm.

In Figure 6,

concentrations are reported as the absorbance units at 525 nm.
Quantitation of Heparin vs Heparin with Known Interfering Compounds

10000
9000
8000

Heparin

A525 Units

7000
6000
5000

Heparin +
Pluronic +
Glucose

4000
3000
2000
1000
0
Start

SepPak

Permeate #1 Retentate #1 Permeate #2 Retentate #2 Permeate #3 Retentate #3

Figure 6: Recovery of heparin from water or known interfering compounds (Pluronic
and glucose) during each stage of a GAG purification experiment using liquid
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R
centrifugal concentrators. Error bars represent the standard deviation of triplicate runs of
the GAG purification experiment.

Isolating Heparin from Interfering Components in Fresh Medium
To isolate heparin from interfering components in fresh medium, a GAG purification
experiment utilizing liquid chromatography and ultrafiltration was conducted. Three
samples (a 5-mL solution of 2 mg/mL of heparin in water, a 5-mL solution of 2 mg/mL
of heparin in medium, and a 5-mL solution of 1 mL of medium in water) were purified by
liquid chromatography using Sep-Pak C-18 cartridges and ultrafiltration using Vivaspin
15R centrifugal concentrators. The revised microcarbazole assay #2 was performed to
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detect the concentration of heparin by measuring the absorbance at 525 nm. In Figure 7,
concentrations are reported as the absorbance units at 525 nm.
Fresh Medium Isolation of Heparin
10000
9000
8000
Heparin

A525 Units

7000
6000

Heparin +
Medium

5000
4000

Medium

3000
2000
1000
0
Start

SepPak

Permeate #1 Retentate #1 Permeate #2 Retentate #2 Permeate #3 Retentate #3

Figure 7: Recovery of heparin from water, heparin from fresh medium, or medium in
water during each stage of a GAG purification experiment using liquid chromatography
with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R centrifugal
concentrators. Error bars represent the standard deviation of triplicate runs of the GAG
purification experiment.

Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #1
To determine how much heparin-like glycosaminoglycans could be recovered from
conditioned medium sample #1, a GAG purification experiment was conducted using
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin
15R centrifugal concentrators. A sample was not taken after the first centrifugation. The
revised microcarbazole assay #2 was performed in triplicate to detect the concentration of
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heparin by measuring the absorbance at 525 nm. In Figure 8, concentrations are reported
as the absorbance units at 525 nm. The amount recovered was 15.9 µg/mL.
400
350

Total A 525 units

300
250
200
150
100
50
0
Start

Retentate #1
Sample

Retentate #2

Figure 8: Recovery of heparin-like glycosaminoglycans from conditioned medium
sample #1 during each stage of GAG purification experiment using liquid
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R
centrifugal concentrators.

The revised microcarbazole assay #2 was performed in

triplicate.

Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #2
To determine how much heparin-like glycosaminoglycans could be recovered from
conditioned medium sample #2, a GAG purification experiment was conducted using
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin
15R centrifugal concentrators. The revised microcarbazole assay #2 was performed in
triplicate to detect the concentration of heparin by measuring the absorbance at 525 nm.
In Figure 9, concentrations are reported as the absorbance units at 525 nm. The amount
recovered was 20.6 µg/mL.
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Total A 525 units
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Retentate #3

Figure 9: Recovery of heparin-like glycosaminoglycans from conditioned medium
sample #2 during each stage of a GAG purification experiment using liquid
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R
centrifugal concentrators.

The revised microcarbazole assay #2 was performed in

triplicate.

Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #3
To determine how much heparin-like glycosaminoglycans could be recovered from
conditioned medium sample #3, a GAG purification experiment was conducted using
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin
15R centrifugal concentrators. The revised microcarbazole assay #2 was performed in
triplicate to detect the concentration of heparin by measuring the absorbance at 525 nm.
In Figure 10, concentrations are reported as the absorbance units at 525 nm. The amount
recovered was 10.0 µg/mL.
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Figure 10: Recovery of heparin-like glycosaminoglycans from conditioned medium
sample #3 during each stage of a GAG purification experiment using liquid
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R
centrifugal concentrators.

The revised microcarbazole assay #2 was performed in

triplicate.

E. Comparing Old GAG Purification Method & New GAG Purification Method
To compare the old and new GAG purification methods, three trials of each protocol
were performed using the same conditioned media sample. The revised microcarbazole
assay #2 was performed in duplicate to determine the concentration of heparin by
measuring the absorbance at 525 nm. In Figure 11, the concentrations of the heparin-like
glycosaminoglycans recovered are reported. Both protocols were repeatable, and the new
GAG protocol yielded a higher concentration.
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1.4

Comparing GAG Purification Protocols

Concentration (µg/mL)

1.2
1
0.8
0.6
0.4
0.2
0
Old Protocol

New Protocol

Figure 11: Recovery of heparin-like glycosaminoglycans from conditioned media using
the old and new GAG purification methods. The revised microcarbazole assay #2 was
performed in duplicate. Error bars represent the standard deviation of triplicate runs of
the GAG purification experiments.
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Discussion
We were able to develop a new GAG purification method that utilized liquid
chromatography using Waters Sep-Pak C-18 classic cartridges and ultrafiltration using
Sartorius Vivaspin 15R centrifugal concentrators. Compared to the old GAG purification
method, the new GAG purification method reduces the required time from 3 days to less
than 4 hours and the cost from $38.18 to $22.61 per sample (Table 3).

Table 3: The costs per sample to run the old GAG purification method and new GAG
purification method. The manufacturer website links are in the appendix.

Item
Sep-Pak C18 Classic
Cartridge
Sartorius Vivaspin 15R
Centrifugal
Concentrators

New GAG Purification Protocol
Price Whole Items Per Price Per
Set ($)
Set
Item ($)
218
50
4.36

457.31

48

9.53

Items
Needed
3

Total
Price ($)
13.08

1

9.53

Total Price Per Sample

Item
Amicon Ultra-15
Centrifugal Filter Units
Syringe Filter, PVDF,
0.22µm, 30mm
Diameter, Sterile
Amicon Ultra-0.5 mL
Centrifugal Filters
Sartorius Vivapure Q
Mini H IEX Spin
Columns

22.61

Old GAG Purification Protocol
Price Whole Items Per Price Per
Set ($)
Set
Item ($)
281
24
11.71

Items
Needed
1

Total
Price ($)
11.71

58

30

1.93

1

1.93

386

96

4.02

2

8.04

198

24

8.25

2

16.50

Total Price Per Sample
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38.18

Our study first confirmed that Sep-Pak C-18 cartridges could remove Pluronic
from solution. One Sep-Pak was sufficient for the removal of Pluronic alone, but since
the conditioned medium samples needed 3 Sep-Pak cartridges for the maximum removal
of color, we used that standard for all our experiments except for the three experiments
using conditioned medium samples #1, #2, and #3 since these experiments were
conducted before we determined that 3 Sep-Pak cartridges was optimal.
We also showed that ultrafiltration with Vivaspin centrifugal concentrators could
remove almost all the glucose while retaining almost all the heparin in water. However,
we observed a large deviation from 100% in the final retentate of the heparin experiment.
We suggest that this may have resulted from the fact that glucose interferes with the
microcarbazole assay and can give either diminished or increased absorbance depending
on the amount of charring that results from the high temperature required by the assay.
In addition, the microcarbazole assay was found to be prone to contamination from the
covering film and is more sensitive to errors when pipetting from one plate to another.
As a result, the microcarbazole assay was revised to a lower temperature using a hot plate
instead of a thermal cycler to heat the samples. It was evident from the heparin standard
curve that this method worked to quantitate the heparin and that one hour, which had the
most linear curve, was the optimal time. Further, using a repeater pipette to create the
standard curve and add the reagents increased the accuracy. Revising the microcarbazole
assay also reduced the amount of time required for the microcarbazole assay to one hour.
We moved forward with the Vivaspin 15R centrifugal concentrators to work with
larger sample volumes. Using the new GAG purification method, we were able to isolate
almost all the heparin from glucose and Pluronic in solution, observing that most
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interference was removed in the permeate resulting from the Vivaspin centrifugal
concentrators. We were also able to isolate heparin from other potentially interfering
contaminants in fresh medium, again observing the removal of interference following the
chromatography and ultrafiltration steps. Medium lacking heparin showed no reaction
when the retentate was assayed by the microcarbazole assay, showing that the interfering
compounds were removed in the permeate.
We then showed that the new GAG purification method recovered varying
amounts of heparin-like glycosaminoglycans from three different conditioned medium
samples.

Conditioned medium sample #3 required a longer centrifugation time,

suggesting that different conditioned medium samples may require varying centrifugation
times. We determined that, when the edge of the membrane was oriented towards the
center of the centrifuge, a 45-minute spin achieved our desired retentate volume below
0.5 mL, so we decided that 45 minutes was the optimal time for each centrifugation.
We were then able to determine and compare the amount of heparin-like
glycosaminoglycans recovered from the old and new GAG purification methods. We
found that the new purification method recovered a higher concentration, which we
presumed was because the old purification method had an anion-exchange step that was
selective for the most highly charged glycosaminoglycans. Future work will focus on
analyzing and comparing the constituents of these samples.
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Appendix I
Links to the manufacturer websites for each item used in the old GAG purification
method and new GAG purification method.

Old GAG Purification Method
Amicon Ultra-15 Centrifugal Filter Units:
http://www.emdmillipore.com/US/en/product/Amicon-Ultra-15-Centrifugal-FilterUnits,MM_NF-C7715#ordering-information
Syringe Filter, PVDF, 0.22µm, 30mm Diameter, Sterile:
https://www.celltreat.com/syringe-filter-pvdf-022µm-30mm-diameter-sterile
Amicon Ultra-0.5 mL Centrifugal Filters:
http://www.emdmillipore.com/US/en/product/Amicon-Ultra-0.5nbspmL-Centrifugal-Filtersfor-DNA-and-Protein-Purification-and-Concentration,MM_NF-C82301#orderinginformation
Sartorius Vivapure Q Mini H IEX Spin Columns:
https://www.fishersci.de/shop/products/sartorius-vivapure-q-mini-h-iex-spincolumns/11760855
New GAG Purification Method
Sep-Pak C18 Classic Cartridge:
http://www.waters.com/waters/partDetail.htm?partNumber=WAT051910&xcid=ext5005&gc
lid=Cj0KCQjw2pXXBRD5ARIsAIYoEbfQmx4mNygOawQhD7kj1zZXFITm8T9IBcFrZvg
EvanbESZwuSsU3ZoaAtbXEALw_wcB
Sartorius Vivaspin 15R Centrifugal Concentrators:
https://www.fishersci.com/shop/products/sartorius-vivaspin-15r-centrifugal-concentrators8/p-4187753
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